Abstract:Abstract Background The transplantation of neural stem/progenitor cells (NS/PCs) at the sub-acute phase of spinal cord injury, but not at the chronic phase, can promote functional recovery. However, the reasons for this difference and whether it involves the survival and/or fate of grafted cells under these two conditions remain unclear. To address this question, NS/PC transplantation was performed after contusive spinal cord injury in adult mice at the sub-acute and chronic phases. Results Quantitative analyses using bio-imaging, which can noninvasively detect surviving grafted cells in living animals, revealed no significant difference in the survival rate of grafted cells between the sub-acute and chronic transplantation groups. Additionally, immunohistology revealed no significant difference in the differentiation phenotypes of grafted cells between the two groups. Microarray analysis revealed no significant differences in the expression of genes encoding inflammatory cytokines or growth factors, which affect the survival and/or fate of grafted cells, in the injured spinal cord between the sub-acute and chronic phases. By contrast, the distribution of chronically grafted NS/PCs was restricted compared to NS/PCs grafted at the sub-acute phase because a more prominent glial scar located around the lesion epicenter enclosed the grafted cells. Furthermore, microarray and histological analysis revealed that the infiltration of macrophages, especially M2 macrophages, which have anti-inflammatory role, was significantly higher at the sub-acute phase than the chronic phase. Ultimately, NS/PCs that were transplanted in the sub-acute phase, but not the chronic phase, promoted functional recovery compared with the vehicle control group. Conclusions The extent of glial scar formation and the characteristics of inflammation is the most remarkable difference in the injured spinal cord microenvironment between the sub-acute and chronic phases. To achieve functional recovery by NS/PC transplantation in cases at the chronic phase, modification of the microenvironment of the injured spinal cord focusing on glial scar formation and inflammatory phenotype should be considered.

Glial Implications in Transplantation Therapy of Spinal Cord Injury.

Transplantation Strategies for Spinal Cord Injury Based on Microenvironment Modulation

Stem Cells: Current Approach and Future Prospects in Spinal Cord Injury Repair

Stem Cell Transplantation: A Promising Therapy for Spinal Cord Injury.

The Application of Neural Stem/Progenitor Cells for Regenerative Therapy of Spinal Cord Injury

Astrocyte Transplantation for Spinal Cord Injury: Current Status and Perspective

A Brief Summary of Current Therapeutic Strategies for Spinal Cord Injury

Time-dependent changes in the microenvironment of injured spinal cord affects the therapeutic potential of neural stem cell transplantation for spinal cord injury

Spinal cord injury: pathophysiology, treatment strategies, associated challenges, and future implications

Cell Transplantation and Neuroengineering Approach for Spinal Cord Injury Treatment: A Summary of Current Laboratory Findings and Review of Literature

Repair of the Injured Spinal Cord by Schwann Cell Transplantation

Cell Transplantation and Neuroengineering Approach for Spinal Cord Injury Treatment: A Summary of Current Laboratory Findings and Review of Literature.

Transplanting neural progenitor cells to restore connectivity after spinal cord injury

The roles of neural stem cells in myelin regeneration and repair therapy after spinal cord injury

Research status of cell transplantation for spinal cord injury repair

Advances in stem cell transplantation for spinal cord injury

Schwann Cell Transplantation for Spinal Cord Injury Repair: Its Significant Therapeutic Potential and Prospectus

Challenges in advancing Schwann cell transplantation for spinal cord injury repair

Current Advancements in Spinal Cord Injury Research—Glial Scar Formation and Neural Regeneration

Microglia: a promising therapeutic target in spinal cord injury

Progress in clinical trials of cell transplantation for the treatment of spinal cord injury: how many questions remain unanswered?